PHARMOVAN
Timeline
52 events since 1989Board
Capital
Filings
Financial
Establishments
Address
19901995200020052010201520202025
The 2026 accounts are due by 31-07-2027.
2026
Annual accounts 2025 filed PDFabbreviated format · 58 days before the deadline
2025
Registered in the Peppol Directory Reachable for e-invoices through 0208:0439974380
Annual accounts 2024 filed PDFabbreviated format · 58 days before the deadline
2024
Highest result from 2007 to 2025 net €179,564 ▲22.1% The operating result of €218,002 and the net result of €179,564 are both a record.
Annual accounts 2023 filed PDFabbreviated format · 20 days late
2023
Annual accounts 2022 filed PDFabbreviated format · 17 days late
Purpose change · Amendment of the articles“De exploitatie,huur en verhuur van één of meer apotheken; Het verzorgen van vervangingen van en voor één of…” (deed in Dutch) · General meeting of 07-06-20234 points ▸
- General meeting, 07-06-2023
- Purpose change, “De exploitatie,huur en verhuur van één of meer apotheken; Het verzorgen van vervangingen van en voor één of meer apotheken alsook de organisatie ervan…” (deed in Dutch)
- Capital, €61,500, 60 shares
- Registered office clause, Aarschotsesteenweg 537
- The deed holds 3 more points.
2022
Annual accounts 2021 filed PDFabbreviated format · 17 days before the deadline
2021
2 directors reappointed and (managing director) · acts as permanent representative · General meeting of 20-05-20216 points ▸
- General meeting, 20-05-2021
- Director reappointment,
- Director reappointment,
- Permanent representative,
- Board meeting, 20-05-2021
- Director reappointment, (managing director)
Annual accounts 2020 filed PDFabbreviated format · 3 days late
2020
Annual accounts 2019 filed PDFabbreviated format · 33 days late
2019
Annual accounts 2018 filed PDFabbreviated format · 21 days late
2018
Annual accounts 2017 filed PDFabbreviated format · 8 days late
2017
Annual accounts 2016 filed PDFabbreviated format · 8 days late
2016
Annual accounts 2015 filed PDFabbreviated format · 31 days before the deadline
2015
Annual accounts 2014 filed PDFabbreviated format · 46 days before the deadline
1 director appointed, 1 resignation, 2 reappointments appointed as managing director · and reappointed · acts as permanent representative · Board meeting of 14-01-20156 points ▸
- Board meeting, 14-01-2015
- Director appointment, (managing director)
- Director reappointment,
- Permanent representative,
- Director reappointment,
- Director resignation,
2014
Liquidity more than doubled current ratio 3.69 The current ratio rises from 1.73 to 3.69. Short-term debt falls from €335,111 to €132,452.
Amendment of the articles1 point ▸
- Capital, €61,500, 60 shares
- The deed holds 4 more points.
Annual accounts 2013 filed PDFabbreviated format · 48 days before the deadline
2013
1 director appointed, 2 resignations, 1 reappointment and resign · appointed · acts as permanent representative · General meeting of 01-07-201310 points ▸
- General meeting, 01-07-2013
- Board meeting, 01-07-2013
- Director resignation,
- Director discharge,
- Director resignation,
- Director discharge,
- Director appointment,
- Permanent representative,
- Director reappointment,
- Director reappointment, (managing director)
Back to profit net €54,265 The net result is €54,265, after one loss-making year.
Annual accounts 2012 filed PDFabbreviated format · 31 days late
Demerger: PHARMOVAN splits off to APOTHEEK CHRIS MORTELMANSThe capital rose from €61,973.38 to €135,542.56 · The capital fell from €135,542.56 to €61,500 · appointed as manager6 points ▸
- Capital increase, €73,569.18
- Power of attorney,
- Power of attorney,
- Director appointment, (manager)
- Capital decrease, €74,042.56
- Net-asset statement, 31-10-2011
- The deed holds 10 more points.
2012
Weakest financial year net -€53,010 The net result drops to -€53,010, the lowest from 2007 to 2025. It recovers the following year.
Demerger proposal: PHARMOVAN splits off to Apotheek Chris Mortelmans holds 300 shares · holds 300 shares · holds 30 shares6 points ▸
- holds 300 shares
- holds 300 shares
- Accounting effect, 01-11-2011
- Capital, €61,973.38, 60 shares
- holds 30 shares
- holds 30 shares
- The deed holds 15 more points.
Annual accounts 2011 filed PDFabbreviated format · 24 days late
Amendment of the articles PDFCapital €61,500, annual accounts 2012
Demerger proposal: PHARMOVAN splits off to Apotheek Mortelmans bvbaBoard meeting of 25-01-20121 point ▸
- Board meeting, 25-01-2012
- The deed holds 1 more point.
2011
Annual accounts 2010 filed PDFabbreviated format · 115 days late
2010
Back to profit net €9,399 The net result is €9,399, after 2 loss-making years.
Annual accounts 2009 filed PDFabbreviated format · 1 day before the deadline
2009
Annual accounts 2008 filed PDFabbreviated format · 6 days before the deadline
2008
Annual accounts 2007 filed PDFabbreviated format · 5 days before the deadline
2007
Annual accounts 2006 filed PDFabbreviated format · 10 days late
2006
Annual accounts 2005 filed PDFabbreviated format
2005
Annual accounts 2004 filed PDFabbreviated format
2004
Annual accounts 2003 filed PDFabbreviated format
2003
Annual accounts 2002 filed PDFabbreviated format
2002
Annual accounts 2001 filed PDFabbreviated format
2001
Annual accounts 2000 filed PDFabbreviated format
2000
Annual accounts 1999 filed PDFabbreviated format
1999
Annual accounts 1998 filed PDFabbreviated format
1998
Annual accounts 1997 filed NBBabbreviated format
1996
Annual accounts 1995 filed NBBabbreviated format
1995
Annual accounts 1994 filed NBBabbreviated format
Annual accounts 1993 filed NBBabbreviated format
1993
Annual accounts 1992 filed NBBabbreviated format
1992
Annual accounts 1991 filed NBBabbreviated format
1991
Annual accounts 1990 filed NBBabbreviated format
1990
First establishment Aarschotsesteenweg 537, Leuven
1989
Incorporation published on 10-02-1990
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank